OBJECTIVES:  Allergic asthma (AA) and allergic rhinitis (AR) are chronic global health problems that can have a significantly detrimental effect on quality of life and healthcare costs. The prevalence of AR in EU is between 17.8% and 26%. ACARIZAX® economic models attempt to capture the costs and health consequences of treatment for house dust mite (HDM) AR and HDM AA patients. METHODS:  Both models followed a decision tree structure. The analyses estimate the total costs and quality-adjusted life-years (QALYs) for the adult patient receiving ACARIZAX® in addition to pharmacotherapy and placebo plus pharmacotherapy (based on MITRA/MERIT trials) over a conservative five year period. The effect obtained in both groups in the trials was assumed to be sustained throughout the 5 years. An annual discount rate of 5% was applied for both costs and QALYs. Costs were estimated by taking healthcare utilisation values from MERIT and MITRA trials. The effectiveness of ACARIZAX® and pharmacotherapy was determined by the utility scores. One-way deterministic sensitivity analyses (DSA) were undertaken. RESULTS:  Both base case scenarios indicated cost effectiveness of ACARIZAX® in Slovakia. For the adult patients with persistent moderate to severe HDM AR the ICER was 9,969 EUR. For the adult patients with HDM AA not well controlled by inhaled corticosteroids and associated with mild to severe HDM AR the ICER was 9,689 EUR. CONCLUSIONS: Results indicate that according to current Slovak 2016 threshold (20,592 EUR), ACARIZAX^® is cost effective in patients with persistent moderate to severe HDM AR despite use of symptom-relieving medication, and also in HDM AA patients not well controlled by inhaled corticosteroids and associated with mild to severe HDM AR. When the unit price of ACARIZAX^® and resources used were altered, the results of the analysis did not change significantly, and the treatment remained cost effective in both ranges tested.